Does the cancer-cystatin-C-TREM2 pathway protect against tau pathology and other AD hallmarks beyond amyloid?¶
Notebook ID: nb-SDA-2026-04-26-gap-pubmed-20260410-150544-e3a2eab9-debate · Analysis: SDA-2026-04-26-gap-pubmed-20260410-150544-e3a2eab9-debate
Domain: neurodegeneration · Date: 2026-04-25
Research Question¶
The abstract focuses exclusively on amyloid plaque reduction, leaving unknown whether this pathway addresses tau tangles, neuroinflammation, or synaptic loss. Since AD is multifactorial, understanding the full therapeutic scope is essential for clinical translation.
Gap type: open_question Source paper: Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystatin-c activation of TREM2. (2026, Cell, PMID:41576952)
Debate Summary¶
Debate transcript not available for this analysis.
Hypotheses Ranked by Composite Score¶
Total hypotheses: 8
| Title | Composite | Confidence | Novelty | Feasibility | Impact |
|---|---|---|---|---|---|
| Anti-inflammatory microglial reprogramming via cystatin-C/TREM2 axis | 0.64 | 0.72 | 0.55 | 0.8 | 0.65 |
| Peri-plaque tau seeding restraint via TREM2-competent microglia | 0.59 | 0.6 | 0.65 | 0.65 | 0.6 |
| Synaptic protection via microglial/complement normalization | 0.56 | 0.55 | 0.5 | 0.6 | 0.65 |
| TREM2-dependent microglial phagocytosis of tau seeds | 0.53 | 0.5 | 0.6 | 0.55 | 0.55 |
| Synergistic reduction of amyloid-tau interaction through secondary effects | 0.5 | 0.65 | 0.25 | 0.7 | 0.4 |
| Tumor-derived extracellular vesicles as TREM2 ligands | 0.49 | 0.45 | 0.7 | 0.45 | 0.5 |
| TREM2-independent neuronal protection via cystatin-C/LRP2 signaling | 0.41 | 0.35 | 0.5 | 0.3 | 0.4 |
| Direct cystatin C inhibition of tau aggregation | 0.39 | 0.3 | 0.55 | 0.3 | 0.45 |
Knowledge Graph Edges¶
No KG edges found for this analysis.
Key Citations¶
No citations found for this analysis.